InMed Pharmaceuticals Inc (NASDAQ: INM) shares are trading lower after the company released safety and efficacy results from its Phase 2 clinical trial (755-201-EB) for symptoms related to Epidermolysis Bullosa (EB). The Phase 2 Trial enrolled 19 patients, with data from one patient excluded from efficacy analysis due to protocol deviation. Chronic itch improved in 12 patients (66.7%), with some patients showing the same level of improvement with INM-755cannabinol (CBN) cream as with the control
Topics for discussion include: - The Big Picture Status of Genomics in Mesothelioma Litigation - Recent Statistical Analyses of Genetically Engineered Mice Reject.
Small changes to the way COVID-19 vaccine side-effect rates are framed and communicated have meaningful impacts on individuals' vaccination intentions.
Employers have a practice of periodically conducting statistical analyses of employee compensation, under attorney-client privilege, to identify potential areas of risk related to pay equity concerns. These analyses are usually focused on gender and race or national origin.